Boston Scientific's Public Offering: Prelude to Deals?
Executive Summary
After Boston Scientific's successful public offering, Boston's stock price was up $46.50 on July 16, 1999, suggesting investors are growing confident that Boston Scientific can rejoin the ranks as one of the leading big-cap device companies in terms of earnings and growth. For non-investors, the public offering raises another question: will Boston Scientific also return to form as one of the device industry's most aggressive acquirers of other companies?
You may also be interested in...
Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.